Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952999 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL16117460 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL1295960 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL15590800 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL2953605 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL16117467 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL30850208 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL3944070 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL12653679 | 0.98 | SLC6A2 (0.49) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL13081194 | 0.98 | SLC6A2 (0.49) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576803-B1 | PREPARATION OF (3aS,7aR)-HEXAHYDROISOBENZOFURAN-1(3H)-ONE BY CATALYZED BIOLOGICAL RESOLUTION OF DIMETHYL CYCLOHEXANE-1,2-DICARBOXYLATE | BGP PRODUCTS OPERATIONS GMBH (CH) | 2019-07-10 | — | — | EP | claimed |
| US-9080193-B2 | Preparation of (3aS,7aR)-hexahydroisobenzofuran-1(3H)-one by catalyzed biological resolution of dimethyl cyclohexane-1,2-dicarboxylate | ABBVIE INC. (US) | 2015-07-14 | — | — | US | claimed |
| US-20130273618-A1 | PREPARATION OF (3aS,7aR)-HEXAHYDROISOBENZOFURAN-1(3H)-ONE BY CATALYZED BIOLOGICAL RESOLUTION OF DIMETHYL CYCLOHEXANE-1,2-DICARBOXYLATE | ABBOTT PRODUCTS OPERATIONS AG (CH) | 2013-10-17 | — | — | US | claimed |
| EP-2576803-A2 | PREPARATION OF (3aS,7aR)-HEXAHYDROISOBENZOFURAN-1(3H)-ONE BY CATALYZED BIOLOGICAL RESOLUTION OF DIMETHYL CYCLOHEXANE-1,2-DICARBOXYLATE | Abbott Products Operations AG (CH) | 2013-04-10 | — | — | EP | claimed |
| WO-2011149938-A2 | PREPARATION OF (3aS,7aR)-HEXAHYDROISOBENZOFURAN-1(3H)-ONE BY CATALYZED BIOLOGICAL RESOLUTION OF DIMETHYL CYCLOHEXANE-1,2-DICARBOXYLATE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-12-01 | — | — | WO | claimed |
| WO-2025043079-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LHOTSE BIO, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-10729778-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2020-08-04 | — | — | US | disclosed |
| EP-2576803-B1 | PREPARATION OF (3aS,7aR)-HEXAHYDROISOBENZOFURAN-1(3H)-ONE BY CATALYZED BIOLOGICAL RESOLUTION OF DIMETHYL CYCLOHEXANE-1,2-DICARBOXYLATE | BGP PRODUCTS OPERATIONS GMBH (CH) | 2019-07-10 | — | — | EP | disclosed |
| US-20190105400-A1 | Carrier-Linked Treprostinil Prodrugs | ASCENDIS PHARMA A/S (DK) | 2019-04-11 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| EP-2978313-B1 | PROCESS OF MAKING PROSTACYCLIN COMPOUNDS WITH LINKER THIOL AND PEGYLATED FORMS | UNITED THERAPEUTICS CORP (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9872864-B2 | Sustained release composition of prostacyclin | ASCENDIS PHARMA A/S (DK) | 2018-01-23 | — | — | US | disclosed |
| US-5239078-A | Collagenase enzyme inhibitors | GLYCOMED INCORPORATED (US) | 1993-08-24 | — | — | US | disclosed |
| WO-1993013741-A2 | INHIBITION OF ANGIOGENESIS BY SYNTHETIC MATRIX METALLOPROTEASE INHIBITORS | GLYCOMED, INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5189178-A | Preventing protein destruction | GALARDY RICHARD E (US) | 1993-02-23 | — | — | US | disclosed |
| US-5183900-A | Matrix metalloprotease inhibitors | GALARDY RICHARD E (US) | 1993-02-02 | — | — | US | disclosed |
| WO-1992009563-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GLYCOMED, INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009556-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GALARDY RICHARD E (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009282-A1 | TREATMENT FOR TISSUE ULCERATION | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5114953-A | Peptides | UNIVERSITY OF FLORIDA (US) | 1992-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10729778-B2 | Carrier-linked treprostinil prodrugs | PAH, SLC16A1, SLC34A3 | SLC6A2 27/4885SLC6A4 117/4885CYP2C19 86/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | SLC6A2 4344/4885SLC6A4 4083/4885CYP2C19 981/4885 |
| US-20190105400-A1 | Carrier-Linked Treprostinil Prodrugs | PAH, TK1, SLC16A1 | SLC6A2 31/4885SLC6A4 93/4885CYP2C19 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.